Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Persistent Pulmonary Hypertension in Corrected Valvular Heart Disease: Hemodynamic Insights and Long‐Term Survival

  • Bermejo, Javier
  • González-Mansilla, Ana
  • Mombiela, Teresa
  • Fernández, Ana I.
  • Martínez-Legazpi, Pablo
  • Yotti, Raquel
  • Evangelista Masip, Artur
Insuficiència cardíaca; Hipertensió pulmonar; Malaltia valvular cardíaca, Insuficiencia cardiaca; Hipertensión pulmonar; Enfermedad valvular cardíaca, Heart failure; Pulmonary hypertension; Valvular heart disease, Background The determinants and consequences of pulmonary hypertension after successfully corrected valvular heart disease remain poorly understood. We aim to clarify the hemodynamic bases and risk factors for mortality in patients with this condition. Methods and Results We analyzed long‐term follow‐up data of 222 patients with pulmonary hypertension and valvular heart disease successfully corrected at least 1 year before enrollment who had undergone comprehensive hemodynamic and imaging characterization as per the SIOVAC (Sildenafil for Improving Outcomes After Valvular Correction) clinical trial. Median (interquartile range) mean pulmonary pressure was 37 mm Hg (32–44 mm Hg) and pulmonary artery wedge pressure was 23 mm Hg (18–26 mm Hg). Most patients were classified either as having combined precapillary and postcapillary or isolated postcapillary pulmonary hypertension. After a median follow‐up of 4.5 years, 91 deaths accounted for 4.21 higher‐than‐expected mortality in the age‐matched population. Risk factors for mortality were male sex, older age, diabetes mellitus, World Health Organization functional class III and higher pulmonary vascular resistance—either measured by catheterization or approximated from ultrasound data. Higher pulmonary vascular resistance was related to diabetes mellitus and smaller residual aortic and mitral valve areas. In turn, the latter correlated with prosthetic nominal size. Six‐month changes in the composite clinical score and in the 6‐minute walk test distance were related to survival. Conclusions Persistent valvular heart disease–pulmonary hypertension is an ominous disease that is almost universally associated with elevated pulmonary artery wedge pressure. Pulmonary vascular resistance is a major determinant of mortality in this condition and is related to diabetes mellitus and the residual effective area of the corrected valve. These findings have important implications for individualizing valve correction procedures., This study was funded by the Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, Spain, the European Union–European Regional Development Fund (EC07/90772 and PI19/00649), and the Consorcio de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Persistent pulmonary hypertension in corrected valvular heart disease, Hemodynamic insights and long-term survival

  • Bermejo, Javier|||0000-0002-5241-2758
  • González-Mansilla, Ana|||0000-0003-3578-9606
  • Mombiela, Teresa|||0000-0003-3466-7551
  • Fernández, Ana Isabel|||0000-0002-1509-5191
  • Martínez-Legazpi, Pablo|||0000-0003-0511-7120
  • Yotti, Raquel|||0000-0002-5551-7408
  • García-Orta, Rocío
  • Sánchez Fernández, Pedro Luis|||0000-0002-1402-0526
  • Castaño-Ruiz, Mario
  • Segovia, Javier|||0000-0002-4606-3416
  • Escribano Subias, Pilar|||0000-0002-6640-4839
  • San Román, José Alberto|||0000-0003-0764-0839
  • Borràs, Xavier|||0000-0003-3972-1385
  • Alonso-Gómez, Ángel María|||0000-0003-2945-7509
  • Botas, Javier|||0000-0001-8871-0725
  • Crespo-Leiro, Maria Generosa|||0000-0002-3085-167X
  • Velasco, Sonia
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • López, Amador
  • Muñoz Aguilera, Roberto
  • Jiménez-Navarro, Manuel|||0000-0002-6759-0514
  • González-Juanatey, José R.
  • Evangelista Masip, Arturo|||0000-0001-8182-1174
  • Elízaga, Jaime
  • Martín-Moreiras, Javier
  • González-Santos, José M.|||0000-0001-6145-3992
  • Moreno-Escobar, Eduardo
  • Fernández Avilés, Francisco|||0000-0001-5501-5275
  • García-Robles, José A.
  • Pérez-David, Esther
  • Pérez Del Villar, Candelas|||0000-0002-2464-4893
  • Sanz-Ruiz, Ricardo
  • Gutierrez-Ibanes, Enrique
  • Vázquez, María E.
  • Mur, Ana
  • Benito, Yolanda
  • Barrio, Alicia
  • Vázquez, Alexandra
  • Uribe, Inés
  • González, Mercedes
  • Arribas Jiménez, Antonio|||0000-0001-5995-8174
  • Clemente Lorenzo, M. Milagros
  • Nieto, Alejandro Diego
  • Perez de Prado, Armando|||0000-0003-3283-0597
  • Alonso Rodríguez, David
  • Gómez-Bueno, Manuel|||0000-0002-9764-7518
  • Sayago Silva, Inés
  • Cavero, Miguel Ángel
  • Domínguez Pérez, Laura|||0000-0001-9540-5112
  • Tello De Meneses, Rocío
  • Ruíz Cano, María José|||0000-0001-6884-3280
  • Jiménez López-Guarch, Carmen
  • Mota, Pedro
  • Amorós Galitó, Carmen
  • Belló Mora, M. Concepción
  • Mesa Rubio, Dolores
  • Campuzano, Raquel
  • Marzoa, Raquel
  • Cuenca, José
  • Suberviola, Verónica
  • Beltrán Herrera, Cristina
  • Mora, Laura
  • Sarrión, M. Mar
  • Vaqueriza, David
  • Ferrer, Elena|||0000-0001-5853-8207
  • Cid-Álvarez, Belén
  • Martínez Monzonís, Amparo
  • Arizón, J. M.|||0000-0002-6501-4767
  • Santisteban, Marta|||0000-0003-0625-686X
  • García-Dorado, David|||0000-0002-1126-1279
  • De Teresa, Eduardo
  • Carrasco-Chinchilla, Fernando|||0000-0003-0549-3214
  • Alonso, Joaquín|||0000-0003-4360-5897
BACKGROUND: The determinants and consequences of pulmonary hypertension after successfully corrected valvular heart disease remain poorly understood. We aim to clarify the hemodynamic bases and risk factors for mortality in patients with this condition. METHODS AND RESULTS: We analyzed long-term follow-up data of 222 patients with pulmonary hypertension and valvular heart disease successfully corrected at least 1 year before enrollment who had undergone comprehensive hemodynamic and imaging characterization as per the SIOVAC (Sildenafil for Improving Outcomes After Valvular Correction) clinical trial. Median (interquartile range) mean pulmonary pressure was 37 mm Hg (32-44 mm Hg) and pulmonary artery wedge pressure was 23 mm Hg (18-26 mm Hg). Most patients were classified either as having combined precapillary and postcapillary or isolated postcapillary pulmonary hypertension. After a median follow-up of 4.5 years, 91 deaths accounted for 4.21 higher-than-expected mortality in the age-matched population. Risk factors for mortality were male sex, older age, diabetes mellitus, World Health Organization functional class III and higher pulmonary vascular resistance-either measured by catheterization or approximated from ultrasound data. Higher pulmonary vascular resistance was related to diabetes mellitus and smaller residual aortic and mitral valve areas. In turn, the latter correlated with prosthetic nominal size. Six-month changes in the composite clinical score and in the 6-minute walk test distance were related to survival. CONCLUSIONS: Persistent valvular heart disease-pulmonary hypertension is an ominous disease that is almost universally associated with elevated pulmonary artery wedge pressure. Pulmonary vascular resistance is a major determinant of mortality in this condition and is related to diabetes mellitus and the residual effective area of the corrected valve. These findings have important implications for individualizing valve correction procedures. REGISTRATION: URL: https://www.clini caltr ials.gov; Unique identifier: NCT00862043.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Persistent Pulmonary Hypertension in Corrected Valvular Heart Disease: Hemodynamic Insights and Long‐Term Survival

  • Bermejo, Javier
  • González-Mansilla, Ana
  • Mombiela, Teresa
  • Fernández, Ana I.
  • Martínez-Legazpi, Pablo
  • Yotti, Raquel
  • Evangelista Masip, Artur
Insuficiència cardíaca; Hipertensió pulmonar; Malaltia valvular cardíaca, Insuficiencia cardiaca; Hipertensión pulmonar; Enfermedad valvular cardíaca, Heart failure; Pulmonary hypertension; Valvular heart disease, Background The determinants and consequences of pulmonary hypertension after successfully corrected valvular heart disease remain poorly understood. We aim to clarify the hemodynamic bases and risk factors for mortality in patients with this condition. Methods and Results We analyzed long‐term follow‐up data of 222 patients with pulmonary hypertension and valvular heart disease successfully corrected at least 1 year before enrollment who had undergone comprehensive hemodynamic and imaging characterization as per the SIOVAC (Sildenafil for Improving Outcomes After Valvular Correction) clinical trial. Median (interquartile range) mean pulmonary pressure was 37 mm Hg (32–44 mm Hg) and pulmonary artery wedge pressure was 23 mm Hg (18–26 mm Hg). Most patients were classified either as having combined precapillary and postcapillary or isolated postcapillary pulmonary hypertension. After a median follow‐up of 4.5 years, 91 deaths accounted for 4.21 higher‐than‐expected mortality in the age‐matched population. Risk factors for mortality were male sex, older age, diabetes mellitus, World Health Organization functional class III and higher pulmonary vascular resistance—either measured by catheterization or approximated from ultrasound data. Higher pulmonary vascular resistance was related to diabetes mellitus and smaller residual aortic and mitral valve areas. In turn, the latter correlated with prosthetic nominal size. Six‐month changes in the composite clinical score and in the 6‐minute walk test distance were related to survival. Conclusions Persistent valvular heart disease–pulmonary hypertension is an ominous disease that is almost universally associated with elevated pulmonary artery wedge pressure. Pulmonary vascular resistance is a major determinant of mortality in this condition and is related to diabetes mellitus and the residual effective area of the corrected valve. These findings have important implications for individualizing valve correction procedures., This study was funded by the Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, Spain, the European Union–European Regional Development Fund (EC07/90772 and PI19/00649), and the Consorcio de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV).